Phase II Study of Rituximab Plus Pembrolizumab (MK-3475) in Subjects With Relapsed Follicular Lymphoma
Phase of Trial: Phase II
Latest Information Update: 29 Sep 2017
At a glance
- Drugs Pembrolizumab (Primary) ; Rituximab
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 11 Sep 2017 Planned End Date changed from 1 Jul 2018 to 1 Jul 2019.
- 11 Sep 2017 Planned primary completion date changed from 1 Jul 2018 to 1 Jul 2019.
- 16 Aug 2017 There is addition of new combonation of pembrolizumab, rituximab, and lenalidomide,number of arms has also changed from1 to 2 hence number of patient has also changed from 30 to 100.